|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.50 / 9.29|
Investors in TherapeuticsMD, Inc. saw new options become available today, for the July 21st expiration.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of TherapeuticsMD, Inc.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company's CEO Robert Finizio will present at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las...
Here are Tuesday's top research calls, including downgrades for Cisco Systems and TherapeuticsMD, and new coverage of Costco and J.C. Penney.
Law Offices of Howard G. Smith reminds investors of the upcoming June 19, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise acquired...
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased TherapeuticsMD, Inc.
We'll close our TherapeuticsMD position with a likely major reset to expectations for the balance of 2017 and 2018.
The FDA wants 12-month endometrial safety data on TX-004HR. TherapeuticsMD conducted a single study that lasted just 12 weeks.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it received a Complete Response Letter (CRL) from the U.
The drug maker this morning is going to share the results of an FDA ruling, and we're concerned that the Street will shoot first and ask questions later.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that, based upon the company's expectation that the U.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended March 31, 2017.
Finding some protection against a possibly significant downside event.
During a busy week of earnings and data, we exited 2 positions and initiated a small one.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TherapeuticsMD, Inc.
Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against TherapeuticsMD, Inc.
We exited one position and downgraded another as earnings season heated up.
Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc.
Company commentary this morning adds layer of uncertainty, which warrants being extra cautious.